Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp
(NQ:
LEXX
)
2.240
+0.160 (+7.69%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
November 26, 2024
Via
ACCESSWIRE
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
November 25, 2024
Via
ACCESSWIRE
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
November 20, 2024
Via
ACCESSWIRE
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
November 14, 2024
Via
ACCESSWIRE
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
November 13, 2024
Via
ACCESSWIRE
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
November 07, 2024
Via
ACCESSWIRE
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
October 24, 2024
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups
Via
TheNewswire.com
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
October 24, 2024
Via
ACCESSWIRE
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
October 22, 2024
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups
Via
TheNewswire.com
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
October 22, 2024
Via
ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 16, 2024
Kelowna, British Columbia – October 16, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced...
Via
TheNewswire.com
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 16, 2024
Via
ACCESSWIRE
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 15, 2024
Via
ACCESSWIRE
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
October 09, 2024
Via
ACCESSWIRE
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
September 27, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
October 09, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on Growth of GLP-1 Market Space, Notes Potential for Oral Delivery
October 08, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Updates Current GLP-1 Market
October 08, 2024
Via
ACCESSWIRE
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Strengthen Executive Team in Anticipation of ‘Strong Growth’ into 2025
October 01, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Appoints Michael Shankman as Chief Financial Officer
October 01, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
September 27, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
September 27, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs
September 20, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
September 20, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
September 20, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study
September 17, 2024
Via
Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program
September 13, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
September 06, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
September 06, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO
September 05, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.